Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jelena Urosevic

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Nature Biomedical Engineering|April 24, 2019
Organ-specific metastasesJelena Urosevic, Roger R Gomis
Cell Cycle (Georgetown, Tex.)|December 9, 2014
MAPK signaling control of colon cancer metastasisJelena Urosevic, Angel R Nebreda, Roger R Gomis
Biomed Research International|May 8, 2014
Cancer monitoring methodsAleksandra Nikolic, Oronza Antonietta Botrugno, Jelena Urosevic, et al.
Therapeutic Drug Monitoring|December 14, 2006
Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemiaLidija Dokmanovic, Jelena Urosevic, Dragana Janic, et al.
Molecular Carcinogenesis|June 16, 2009
Using cells devoid of RAS proteins as tools for drug discoveryJelena Urosevic, Eleanor Y M Sum, Victoria Moneo, et al.
The Journal of Biological Chemistry|May 2, 2012
Identification of NOG as a specific breast cancer bone metastasis-supporting geneMaria Tarragona, Milica Pavlovic, Anna Arnal-Estapé, et al.
European Journal of Haematology|February 14, 2004
Severe central nervous system thrombotic events in hemoglobin Sabine patientSonja Pavlovic, Milos Kuzmanovic, Jelena Urosevic, et al.
The Journal of Pathology|April 3, 2016
Tumour stroma-derived lipocalin-2 promotes breast cancer metastasisBilge Ören, Jelena Urosevic, Christina Mertens, et al.
The EMBO Journal|February 13, 2010
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survivalMatthias Drosten, Alma Dhawahir, Eleanor Y M Sum, et al.
Molecular Cancer Therapeutics|September 18, 2020
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768INicolas Floc'h, Sangbin Lim, Sue Bickerton, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Nature Biomedical Engineering|April 24, 2019
Organ-specific metastasesJelena Urosevic, Roger R Gomis
Cell Cycle (Georgetown, Tex.)|December 9, 2014
MAPK signaling control of colon cancer metastasisJelena Urosevic, Angel R Nebreda, Roger R Gomis
Biomed Research International|May 8, 2014
Cancer monitoring methodsAleksandra Nikolic, Oronza Antonietta Botrugno, Jelena Urosevic, et al.
Therapeutic Drug Monitoring|December 14, 2006
Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemiaLidija Dokmanovic, Jelena Urosevic, Dragana Janic, et al.
Molecular Carcinogenesis|June 16, 2009
Using cells devoid of RAS proteins as tools for drug discoveryJelena Urosevic, Eleanor Y M Sum, Victoria Moneo, et al.
The Journal of Biological Chemistry|May 2, 2012
Identification of NOG as a specific breast cancer bone metastasis-supporting geneMaria Tarragona, Milica Pavlovic, Anna Arnal-Estapé, et al.
European Journal of Haematology|February 14, 2004
Severe central nervous system thrombotic events in hemoglobin Sabine patientSonja Pavlovic, Milos Kuzmanovic, Jelena Urosevic, et al.
The Journal of Pathology|April 3, 2016
Tumour stroma-derived lipocalin-2 promotes breast cancer metastasisBilge Ören, Jelena Urosevic, Christina Mertens, et al.
The EMBO Journal|February 13, 2010
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survivalMatthias Drosten, Alma Dhawahir, Eleanor Y M Sum, et al.
Molecular Cancer Therapeutics|September 18, 2020
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768INicolas Floc'h, Sangbin Lim, Sue Bickerton, et al.
Pageof 4